Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
Keiya Uriu, Jumpei Ito, Jiří Zahradník, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 3, pp. 280-281
Open Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
Tomokazu Tamura, Jumpei Ito, Keiya Uriu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 249
Virological characteristics of the SARS-CoV-2 JN.1 variant
Yu Kaku, Kaho Okumura, Miguel Padilla‐Blanco, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 2, pp. e82-e82
Open Access | Times Cited: 178
Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant
Jumpei Ito, Rigel Suzuki, Keiya Uriu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 113
The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
Danyi Ao, Xuemei He, Weiqi Hong, et al.
MedComm (2023) Vol. 4, Iss. 2
Open Access | Times Cited: 100
Virological characteristics of the SARS-CoV-2 BA.2.86 variant
Tomokazu Tamura, Keita Mizuma, Hesham Nasser, et al.
Cell Host & Microbe (2024) Vol. 32, Iss. 2, pp. 170-180.e12
Open Access | Times Cited: 51
Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5
Yu Kaku, Yusuke Kosugi, Keiya Uriu, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 10, pp. e395-e396
Open Access | Times Cited: 49
Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant
Tomokazu Tamura, Takashi Irie, Sayaka Deguchi, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 39
Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants
Ann‐Kathrin Reuschl, Lucy Thorne, Matthew Whelan, et al.
Nature Microbiology (2024) Vol. 9, Iss. 2, pp. 451-463
Open Access | Times Cited: 38
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial
Juleen Gayed, Oyeniyi Diya, Francine S. Lowry, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 118-118
Open Access | Times Cited: 21
A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity
Leire de Campos‐Mata, Benjamin Trinité, Andrea Modrego, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Waning immunity and IgG4 responses following bivalent mRNA boosting
Ninaad Lasrado, Ai‐ris Y. Collier, Jessica Miller, et al.
Science Advances (2024) Vol. 10, Iss. 8
Open Access | Times Cited: 12
Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion
Song Xue, Yuru Han, Fan Wu, et al.
Protein & Cell (2024) Vol. 15, Iss. 6, pp. 403-418
Open Access | Times Cited: 12
Virological characteristics of the SARS-CoV-2 BA.2.86 variant
Tomokazu Tamura, Keita Mizuma, Hesham Nasser, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 28
Virological characteristics of the SARS-CoV-2 JN.1 variant
Yu Kaku, Kaho Okumura, Miguel Padilla‐Blanco, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 27
The Therapeutic Potential of Natural Dietary Flavonoids against SARS-CoV-2 Infection
Zhonglei Wang, Liyan Yang
Nutrients (2023) Vol. 15, Iss. 15, pp. 3443-3443
Open Access | Times Cited: 25
Virological characteristics of the SARS-CoV-2 Omicron XBB.1.16 variant
Daichi Yamasoba, Keiya Uriu, Arnon Plianchaisuk, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 21
A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2
Cai He, Aqu Alu, Lei Hong, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 20
Virological characteristics of the SARS‐CoV‐2 Omicron EG.5.1 variant
Shuhei Tsujino, Sayaka Deguchi, Tomo Nomai, et al.
Microbiology and Immunology (2024) Vol. 68, Iss. 9, pp. 305-330
Open Access | Times Cited: 11
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial
Juleen Gayed, Oyeniyi Diya, Francine S. Lowry, et al.
(2024)
Open Access | Times Cited: 9
Altered receptor binding, antibody evasion and retention of T cell recognition by the SARS-CoV-2 XBB.1.5 spike protein
Dhiraj Mannar, James W. Saville, Chad Poloni, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants
Barbara Mühlemann, Jakob Trimpert, Felix Walper, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 32
Open Access | Times Cited: 8
An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants
Ryuta Uraki, Masaki Imai, Mutsumi Ito, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 7
Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023
Eero Poukka, Jori Perälä, Hanna Nohynek, et al.
Eurosurveillance (2024) Vol. 29, Iss. 37
Open Access | Times Cited: 7
Uncovering the Binding Mechanism of Mutated Omicron Variants via Computational Strategies
Sajjad Haider, Nadeem Ahmad, Muhammad Shafiq, et al.
ACS Omega (2025)
Open Access
Page 1 - Next Page

Scroll to top